On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (delandistrogene moxeparvovec) for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD).
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and Roche Holdings AG (OTC:RHHBY) are collaborating to develop and commercialize gene therapy.
